Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Bladder Cancer, August 2023

Free Subscription


Abstracts

Retrieve all available abstracts of the following 207 articles:
HTML format


 

Single Articles

  1. HEALTHCARE ENGINEERING JO
    Retracted: Clinical Value Analysis of Xiaozheng Decoction Combined with Bladder Perfusion for Postoperative Treatment of Bladder Cancer and Its Effect on Serum miR-143 and miR-92a.
    J Healthc Eng. 2023;2023:9785158.
    PubMed    
    Abstract available

  2. SUN Z, Sun X, Qin G, Li Y, et al
    FTO promotes proliferation and migration of bladder cancer via enhancing stability of STAT3 mRNA in an m6A-dependent manner.
    Epigenetics. 2023;18:2242688.
    PubMed    
    Abstract available

  3. CHEN S, Ran J, Fan Z, Liu M, et al
    Functional status analysis of RNH1 in bladder cancer for predicting immunotherapy response.
    Sci Rep. 2023;13:12625.
    PubMed    
    Abstract available

  4. KLOSKOWSKI T, Fekner Z, Szeliski K, Paradowska M, et al
    Effect of four fluoroquinolones on the viability of bladder cancer cells in 2D and 3D cultures.
    Front Oncol. 2023;13:1222411.
    PubMed    
    Abstract available

  5. GIL DA COSTA RM, Levesque C, Bianchi-Frias D, Chatterjee P, et al
    Pharmacological NF-kappaB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
    Mol Oncol. 2023 Aug 3. doi: 10.1002/1878-0261.13504.
    PubMed    
    Abstract available

  6. ALI AH, Benterud A, Holmoy T, Myro AZ, et al
    Progressive encephalomyelitis with rigidity and myoclonus (PERM) associated with anti-glycine receptor antibodies and urothelial carcinoma: a case report.
    J Med Case Rep. 2023;17:330.
    PubMed    
    Abstract available

  7. FLEISCHMANN M, Rodel C
    [Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer].
    Strahlenther Onkol. 2023 Aug 2. doi: 10.1007/s00066-023-02134.
    PubMed    


  8. ZHONG J, Xu A, Xu P, Su M, et al
    Circ_0000235 targets MCT4 to promote glycolysis and progression of bladder cancer by sponging miR-330-5p.
    Cell Death Discov. 2023;9:283.
    PubMed    
    Abstract available

  9. HAO Y, Zhu Y, Sun F, Xu D, et al
    MicroRNA-30c-5p arrests bladder cancer G2/M phase and suppresses its progression by targeting PRC1-mediated blocking of CDK1/Cyclin B1 axis.
    Cell Signal. 2023 Jul 31:110836. doi: 10.1016/j.cellsig.2023.110836.
    PubMed    
    Abstract available

  10. CHENG Y, Yu H, Li K, Lv J, et al
    Hsa_circ_0003098 promotes bladder cancer progression via miR-377-5p/ACAT2 axis.
    Genomics. 2023 Jul 31:110692. doi: 10.1016/j.ygeno.2023.110692.
    PubMed    
    Abstract available

  11. RIBEIRO DE SOUZA B, Brum Reis I, Cardoso de Arruda Camargo G, Oliveira G, et al
    A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad(R) immunotherapy associated with platelet-rich plasma.
    Int Immunopharmacol. 2023;123:110723.
    PubMed    
    Abstract available

  12. MEHMANDAR-OSKUIE A, Jahankhani K, Rostamlou A, Arabi S, et al
    Molecular landscape of LncRNAs in bladder cancer: From drug resistance to novel LncRNA-based therapeutic strategies.
    Biomed Pharmacother. 2023;165:115242.
    PubMed    
    Abstract available

  13. DEMIRCI A, Ordu M
    The prognostic effect of immunohistochemical staining rates in patients with non-muscle-invasive bladder cancer.
    Indian J Pathol Microbiol. 2023;66:502-510.
    PubMed    
    Abstract available

  14. LI Y, Kong Y, An M, Luo Y, et al
    ZEB1-mediated biogenesis of circNIPBL sustains the metastasis of bladder cancer via Wnt/beta-catenin pathway.
    J Exp Clin Cancer Res. 2023;42:191.
    PubMed    
    Abstract available

  15. CHEN JQ, Salas LA, Wiencke JK, Koestler DC, et al
    Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes.
    Cancer Epidemiol Biomarkers Prev. 2023 Aug 1:EPI-23-0331.
    PubMed    
    Abstract available

  16. FAN Z, Shi H, Luo J, Guo X, et al
    Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band imaging in bladder cancer: A systematic review and network meta-analysis.
    Int J Surg. 2023 Aug 1. doi: 10.1097/JS9.0000000000000592.
    PubMed    
    Abstract available

  17. KUANG X, Zhang Z, Li D, Bao W, et al
    Peptidase inhibitor (PI16) impairs bladder cancer metastasis by inhibiting NF-kappaB activation via disrupting multiple-site ubiquitination of NEMO.
    Cell Mol Biol Lett. 2023;28:62.
    PubMed    
    Abstract available

  18. CHABALLOUT BH, Chang EM, Parikh NR, Min Y, et al
    Assessing utilities for muscle-invasive bladder cancer-related health states.
    Urol Oncol. 2023 Jul 29:S1078-1439(23)00239.
    PubMed    
    Abstract available

  19. JIANG C, Xiao Y, Xu D, Huili Y, et al
    Prognosis Prediction of Disulfidptosis-Related Genes in Bladder Cancer and a Comprehensive Analysis of Immunotherapy.
    Crit Rev Eukaryot Gene Expr. 2023;33:73-86.
    PubMed    
    Abstract available

  20. MICHAEL SN, Masood PF, Sharma U, Bhat FI, et al
    Giant right hydronephrosis with underlying double malignancy: a case report.
    Pan Afr Med J. 2023;45:21.
    PubMed    
    Abstract available

  21. ELSAWY AA, Laymon M, Mansour I, Elghareeb A, et al
    Can we offer additional BCG therapy for three-month BCG refractory high grade/T1, Tis bladder cancer patients?
    Arab J Urol. 2023;21:142-149.
    PubMed    
    Abstract available

  22. AWAD M, Harraz AM, Farg H, Gabr HS, et al
    Microscopic hematuria and pelvic ultrasonography could rule out flexible cystoscopy during surveillance for T1-low grade non-muscle invasive bladder cancer.
    Arab J Urol. 2023;21:150-155.
    PubMed    
    Abstract available

  23. PICHLER R, Diem G, Hackl H, Koutnik J, et al
    Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2.
    Front Immunol. 2023;14:1202157.
    PubMed    
    Abstract available

  24. KOLAT D, Kaluzinska-Kolat Z, Kosla K, Orzechowska M, et al
    LINC01137/miR-186-5p/WWOX: a novel axis identified from WWOX-related RNA interactome in bladder cancer.
    Front Genet. 2023;14:1214968.
    PubMed    
    Abstract available

  25. JIN Y, Huang S, Wang Z
    Identify and validate RUNX2 and LAMA2 as novel prognostic signatures and correlate with immune infiltrates in bladder cancer.
    Front Oncol. 2023;13:1191398.
    PubMed    
    Abstract available

  26. DOU X, Ma X, Meng W, Zhang W, et al
    HEATR3 involved in the cell proliferation, metastasis and cell cycle development of bladder cancer acts as a tumor suppressor.
    Mol Genet Genomics. 2023 Jul 31. doi: 10.1007/s00438-023-02046.
    PubMed    
    Abstract available

  27. BRUCK K, Meijer RP, Boormans JL, Kiemeney LA, et al
    Disease-free survival of patients with muscle invasive bladder cancer treated with radical cystectomy versus bladder preserving therapy: a nationwide study.
    Int J Radiat Oncol Biol Phys. 2023 Jul 28:S0360-3016(23)07686.
    PubMed    
    Abstract available

  28. WIBERG E, Vega A, Eriksson V, Banday V, et al
    A Validation Study of cT-Categories in the Swedish National Urinary Bladder Cancer Register-Norrland University Hospital.
    J Pers Med. 2023;13:1163.
    PubMed    
    Abstract available

  29. HSU CY, Yang WT, Lin JH, Lu CH, et al
    Sertindole, an Antipsychotic Drug, Curbs the STAT3/BCL-xL Axis to Elicit Human Bladder Cancer Cell Apoptosis In Vitro.
    Int J Mol Sci. 2023;24:11852.
    PubMed    
    Abstract available

  30. LUCCHESI CA, Vasilatis DM, Mantrala S, Chandrasekar T, et al
    Pesticides and Bladder Cancer: Mechanisms Leading to Anti-Cancer Drug Chemoresistance and New Chemosensitization Strategies.
    Int J Mol Sci. 2023;24:11395.
    PubMed    
    Abstract available

  31. PARK EG, Lee DH, Kim WR, Lee YJ, et al
    Human Endogenous Retrovirus-H-Derived miR-4454 Inhibits the Expression of DNAJB4 and SASH1 in Non-Muscle-Invasive Bladder Cancer.
    Genes (Basel). 2023;14:1410.
    PubMed    
    Abstract available

  32. OSTROWSKI DA, Chelluri RR, Herzig M, Xia L, et al
    Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:3746.
    PubMed    
    Abstract available

  33. DROSOS Y, Konstantakou EG, Bassogianni AS, Nikolakopoulos KS, et al
    Microtubule Dynamics Deregulation Induces Apoptosis in Human Urothelial Bladder Cancer Cells via a p53-Independent Pathway.
    Cancers (Basel). 2023;15:3730.
    PubMed    
    Abstract available

  34. LOZANO F, Raventos CX, Carrion A, Dinares C, et al
    Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?
    Cancers (Basel). 2023;15:3683.
    PubMed    
    Abstract available

  35. MENG X, Li S, He K, Hu H, et al
    Evaluation of Whole-Tumor Texture Analysis Based on MRI Diffusion Kurtosis and Biparametric VI-RADS Model for Staging and Grading Bladder Cancer.
    Bioengineering (Basel). 2023;10:745.
    PubMed    
    Abstract available

  36. YU J, Wu S, Li R, Jiang Y, et al
    Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
    J Hematol Oncol. 2023;16:85.
    PubMed    
    Abstract available

  37. ZHAN Y, Lin J, Liu Y, Chen M, et al
    Correction: Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer.
    J Exp Clin Cancer Res. 2023;42:185.
    PubMed    


  38. LI H, Zhou J, Chen R, Zhu J, et al
    The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma.
    Urol Oncol. 2023;41:356.
    PubMed    
    Abstract available

  39. D'ANDREA D, Shariat SF, Soria F, DI Trapani E, et al
    Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy.
    Minerva Urol Nephrol. 2023;75:452-459.
    PubMed    
    Abstract available

  40. BURGESS EF, Livasy CA, Symanowski JT, Matulay JT, et al
    Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites.
    Urol Oncol. 2023;41:357.
    PubMed    
    Abstract available

  41. CLARK-GARVEY S, Damrauer JS, Milowsky MI
    Cancer Associated Fibroblasts: An Understudied but Critical Component of the Tumor Microenvironment in Urothelial Cancer.
    Eur Urol Oncol. 2023;6:376-377.
    PubMed    


  42. TAKASE R, Hagiya H, Fujimori T, Yokoyama Y, et al
    Super acute-onset disseminated BCG infection: A case report.
    J Infect Chemother. 2023;29:919-921.
    PubMed    
    Abstract available

  43. KAWAMURA K, Miyai K, Sato K, Matsukuma S, et al
    Copy number gain of ACTN4 is associated with poor prognosis in patients with upper urinary tract urothelial carcinoma.
    Cancer Sci. 2023;114:3411-3422.
    PubMed    
    Abstract available

  44. MORGANS AK, Galsky MD, Wright P, Hepp Z, et al
    Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
    Urol Oncol. 2023;41:357.
    PubMed    
    Abstract available

  45. NICOLETTI R, Gauhar V, Castellani D, Enikeev D, et al
    Current Techniques for En Bloc Transurethral Resection of Bladder Tumor: A Hands-on Guide Through the Energy Landscape.
    Eur Urol Focus. 2023;9:567-570.
    PubMed    
    Abstract available

  46. MAFFEZZOLI M, Campobasso D, Rebuzzi SE, Banna GL, et al
    Prognostic models for patients with metastatic urothelial carcinoma: why use them?
    Minerva Urol Nephrol. 2023;75:419-421.
    PubMed    


  47. DRESSLER FF, Hinrichs S, Roesch MC, Perner S, et al
    EpCAM tumor specificity and proteoform patterns in urothelial cancer.
    J Cancer Res Clin Oncol. 2023;149:8913-8922.
    PubMed    
    Abstract available

  48. LIMA W, Wang Y, Miyamoto H
    The impact of routine frozen section analysis during nephroureterectomy or segmental ureterectomy for urothelial carcinoma on final surgical margin status and long-term oncologic outcome.
    Urol Oncol. 2023;41:357.
    PubMed    
    Abstract available

  49. WANG J, Zuo X, Zhang Y, Wang W, et al
    The impact of histological variants in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.
    J Cancer Res Clin Oncol. 2023;149:8279-8288.
    PubMed    
    Abstract available

  50. LIAO CI, Fang HC, Lee PT, Hsu CY, et al
    Trends in the incidence of urothelial carcinoma in Taiwan after the ban on aristolochic acid-containing Chinese herbal preparations, 2001-2018: a national population-based cohort study.
    J Cancer Res Clin Oncol. 2023;149:8201-8211.
    PubMed    
    Abstract available

  51. CAO Y
    A case of rare metachronous four primary carcinoma.
    J Cancer Res Clin Oncol. 2023;149:7471-7477.
    PubMed    
    Abstract available

  52. CHEN T, Zheng Y, Roskos L, Mager DE, et al
    Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma.
    J Pharmacokinet Pharmacodyn. 2023;50:251-265.
    PubMed    
    Abstract available

  53. SJODAHL G, Bernardo C, Eriksson P, Hoglund M, et al
    Tumor Biomarkers for Bacillus Calmette-Guerin Response: What We Get Is Not What We Want.
    Eur Urol Focus. 2023;9:582-583.
    PubMed    
    Abstract available

  54. CELIK B, Kavas G
    Atypical Category of the Johns Hopkins Template Has Higher Risk of Malignancy than the Paris System but the Paris System Is More Applicable for Suspicious Category.
    Acta Cytol. 2023;67:425-433.
    PubMed    
    Abstract available

  55. MUILWIJK T, Akand M, Raskin Y, Jorissen C, et al
    Quality Control Indicators for Transurethral Resection of Bladder Tumor: Results from an Embedded Belgian Multicenter Prospective Registry.
    Eur Urol Oncol. 2023;6:422-430.
    PubMed    
    Abstract available


  56. Correction to "G-protein-coupled receptor 137 accelerates proliferation of urinary bladder cancer cells in vitro".
    Biotechnol Appl Biochem. 2023;70:1560.
    PubMed    



  57. Retraction Statement: KLF8 is required for bladder cancer cell proliferation and migration.
    Biotechnol Appl Biochem. 2023;70:1555.
    PubMed    


  58. LIU L, Sun FZ, Zhang PY, Xiao Y, et al
    Development and validation a model for predicting overall survival of bladder cancer with lung metastasis: a population-based study.
    Eur J Med Res. 2023;28:279.
    PubMed    
    Abstract available

  59. DENG H, Deng L, Chao H, Yu Z, et al
    RAB14 promotes epithelial-mesenchymal transition in bladder cancer through autophagy‑dependent AKT signaling pathway.
    Cell Death Discov. 2023;9:292.
    PubMed    
    Abstract available

  60. HOSOMI T, Shibasaki N, Otsuka H, Uketa S, et al
    [Advanced Bladder Cancer with Multiple Pulmonary Metastases Treated with Paclitaxel/Ifosfamide/Nedaplatin Therapy : Two Case Reports].
    Hinyokika Kiyo. 2023;69:183-188.
    PubMed    
    Abstract available

  61. CONTIERI R, Hensley PJ, Tan WS, Grajales V, et al
    Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin or Early Radical Cystectomy.
    Eur Urol Oncol. 2023 Aug 7:S2588-9311(23)00157-8. doi: 10.1016/j.euo.2023.
    PubMed    
    Abstract available

  62. FONTUGNE J, Xylinas E, Krucker C, Dixon V, et al
    RNA-seq profiling of upper tract urothelial carcinoma: bladder cancer consensus classification relevance, molecular heterogeneity and differential immune signatures.
    Mod Pathol. 2023 Aug 7:100300. doi: 10.1016/j.modpat.2023.100300.
    PubMed    
    Abstract available

  63. DUMONT C, Aregui A, Hauchecorne M, Lefevre M, et al
    Safety and efficacy of preoperative chemotherapy for muscle-invasive bladder cancer in elderly patients.
    World J Urol. 2023 Aug 9. doi: 10.1007/s00345-023-04561.
    PubMed    
    Abstract available

  64. SCANLON L, Canavan J, Babiker Z, Shilling C, et al
    Leiomyoma of the Bladder: A case report and review.
    Ir Med J. 2023;116:792.
    PubMed    


  65. RASMUSSEN AM, Okholm TLH, Knudsen M, Vang S, et al
    Circular stable intronic RNAs possess distinct biological features and are deregulated in bladder cancer.
    NAR Cancer. 2023;5:zcad041.
    PubMed    
    Abstract available

  66. WANG J, Zhu J, Hu J, Wang Z, et al
    A novel in vitro prognostic model of bladder cancer based on urine-derived living tumor cells.
    Genes Dis. 2022;10:2586-2596.
    PubMed    
    Abstract available

  67. TAN W, Gao L, Yuan Y, Huang H, et al
    Relationship between testosterone and male bladder cancer.
    Sci Rep. 2023;13:12881.
    PubMed    
    Abstract available

  68. FU Z, Tian Z, Chen Y, Jia Z, et al
    Analysis of the efficacy of a single subumbilical stoma for bilateral cutaneous ureterostomy after radical cystectomy.
    Eur J Med Res. 2023;28:273.
    PubMed    
    Abstract available

  69. GUO R, Wang L, Bai S, Kang D, et al
    Specific subsets of urothelial bladder carcinoma infiltrating T cells associated with poor prognosis.
    Sci Rep. 2023;13:12801.
    PubMed    
    Abstract available

  70. LEOW JJ, Yong DZ, Chong YL
    Value-based healthcare for bladder cancer patients undergoing robot-assisted radical cystectomy.
    Eur J Surg Oncol. 2023;49:1329-1330.
    PubMed    


  71. HSU FT, Liu WL, Lee SR, Jeng LB, et al
    Unveiling nature's potential weapon: Magnolol's role in combating bladder cancer by upregulating the miR-124 and inactivating PKC-delta/ERK axis.
    Phytomedicine. 2023;119:154947.
    PubMed    
    Abstract available

  72. DEL GIUDICE F, Belladelli F, Glover F, Basran S, et al
    5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (alpha-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data.
    World J Urol. 2023 Aug 7. doi: 10.1007/s00345-023-04551.
    PubMed    
    Abstract available

  73. JIA X, Shkolyar E, Laurie MA, Eminaga O, et al
    Tumor detection under cystoscopy with transformer-augmented deep learning algorithm.
    Phys Med Biol. 2023;68.
    PubMed    
    Abstract available

  74. SUN C, Zhou X, Lou J
    A Survival Model for Patients with Upper Tract Urothelial Carcinoma.
    Arch Esp Urol. 2023;76:357-362.
    PubMed    
    Abstract available

  75. SHUMAN L, Pham J, Wildermuth T, Wu XR, et al
    Urothelium-specific expression of mutationally activated Pik3ca initiates early lesions of non-invasive bladder cancer.
    Am J Pathol. 2023 Aug 4:S0002-9440(23)00272-9. doi: 10.1016/j.ajpath.2023.
    PubMed    
    Abstract available

  76. HUANG L, Jia K, Yao K, Liu D, et al
    Effect of neoadjuvant chemotherapy on survival in patients with T1 high-grade non-muscle-invasive bladder cancer who underwent radical cystectomy.
    Medicine (Baltimore). 2023;102:e34501.
    PubMed    
    Abstract available

  77. WARE AP, Satyamoorthy K, Paul B
    Integrated multiomics analysis of chromosome 19 miRNA cluster in bladder cancer.
    Funct Integr Genomics. 2023;23:266.
    PubMed    
    Abstract available

  78. LIU H, Zhou Z, Yao H, Mao Q, et al
    Robot-assisted radical cystectomy vs open radical cystectomy in patients with bladder cancer: a systematic review and meta-analysis of randomized controlled trials.
    World J Surg Oncol. 2023;21:240.
    PubMed    
    Abstract available

  79. ZHAO X, Chen J, Zhang C, Xie G, et al
    LncRNA AGAP2-AS1 interacts with IGF2BP2 to promote bladder cancer progression via regulating LRG1 mRNA stability.
    Cell Signal. 2023 Aug 2:110839. doi: 10.1016/j.cellsig.2023.110839.
    PubMed    
    Abstract available

  80. ZLOTTA AR, Lajkosz K, Efstathiou JA
    Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed - Authors' reply.
    Lancet Oncol. 2023;24:e325-e326.
    PubMed    


  81. JENA R, Issa R, Perry M
    Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed.
    Lancet Oncol. 2023;24:e324.
    PubMed    


  82. PANT S, Schuler M, Iyer G, Witt O, et al
    Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
    Lancet Oncol. 2023;24:925-935.
    PubMed    
    Abstract available


  83. [First-line maintenance therapy of adult patients with BCG-naive high-risk non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-2
    Aktuelle Urol. 2023;54:272-273.
    PubMed    


  84. CHEN J, Zhang Z, Nie Z, Qiu J, et al
    Effects of intravenous chemotherapy after TURBT for high-risk nonmuscle invasive bladder cancer: results of a retrospective study.
    J Cancer Res Clin Oncol. 2023 Aug 4. doi: 10.1007/s00432-023-05206.
    PubMed    
    Abstract available

  85. ZHENG B, Wang S, Zhang J, Ge C, et al
    Expression, Prognostic Value, and immune infiltration of MTHFD family in bladder cancer.
    Curr Cancer Drug Targets. 2023 Aug 4. doi: 10.2174/1568009623666230804152603.
    PubMed    
    Abstract available

  86. ZENG Z, Wu X, Peng K, Ren D, et al
    Robot-assisted laparoscopic enucleation in the treatment of leiomyosarcoma of urinary bladder: A case report.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023;48:782-788.
    PubMed    
    Abstract available

  87. SHIBUTANI K, Ishikawa K, Mori N
    Uncommon but Clinically Significant: Bacillus Calmette-Guerin (BCG) Infection of the Urinary Tract and its Impact on Quality of Life.
    Am J Case Rep. 2023;24:e940375.
    PubMed    
    Abstract available

  88. JAIN K, Jain E, DiLena R, Saleeb R, et al
    Urachal xanthogranuloma: a rare but important case presenting as a urachal mass.
    BMC Urol. 2023;23:132.
    PubMed    
    Abstract available

  89. TRIPATHI A, Lerner SP
    Poly (ADP-ribose) Polymerase Inhibition in Advanced Urothelial Carcinoma.
    JCO Precis Oncol. 2023;7:e2300293.
    PubMed    


  90. TURNER R, Powari M, Stevenson T
    From haematuria to nephroureterectomy via urine cytology-A case study.
    Cytopathology. 2023;34:494-496.
    PubMed    


  91. WANG S, Zhang D, Bai Y, Liu F, et al
    Clinical Outcomes of Pelvic Lymph Node Dissection Before Versus After Robot-Assisted Laparoscopic Radical Cystectomy.
    J Laparoendosc Adv Surg Tech A. 2023;33:776-781.
    PubMed    
    Abstract available

  92. BAGHERY F, Lau LDW, Mohamadi M, Vazirinejad R, et al
    Risk of urinary tract cancers following arsenic exposure and tobacco smoking: a review.
    Environ Geochem Health. 2023;45:5579-5598.
    PubMed    
    Abstract available

  93. ZHOU L, Shao Z, Liu Y, Yan X, et al
    HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population.
    Oncologist. 2023;28:e617-e624.
    PubMed    
    Abstract available

  94. XUE G, Liu Y, Ji X, Zhang H, et al
    Wound dehiscence in enhanced recovery after open radical cystectomy: A meta-analysis.
    Int Wound J. 2023;20:2634-2639.
    PubMed    
    Abstract available

  95. EUGENIA L, Giovanni A, Andrea M, Maria Rosaria R, et al
    Mucinous appendiceal adenocarcinoma invading the bladder: not always an easy diagnosis. A case report.
    Anticancer Drugs. 2023;34:967-969.
    PubMed    
    Abstract available

  96. SILVA JF, Pereira P, Macedo G
    A rare case of ulcerative colitis following Bacillus Calmette-Guerin therapy.
    Rev Esp Enferm Dig. 2023;115:403.
    PubMed    
    Abstract available

  97. MJAESS G, Diamand R, Aoun F, Assenmacher G, et al
    Cost-analysis of robot-assisted radical cystectomy in Europe: A cross-country comparison.
    Eur J Surg Oncol. 2023;49:1511-1518.
    PubMed    
    Abstract available

  98. GU L, Hu G, Hu J, Wen F, et al
    Construction and comprehensive analysis of a novel prognostic signature associated with immunogenic cell death molecular subtypes in patients with bladder cancer.
    Heliyon. 2023;9:e18848.
    PubMed    
    Abstract available

  99. LIU C, Xu P, Shao S, Wang F, et al
    The value of urinary exosomal lncRNA SNHG16 as a diagnostic biomarker for bladder cancer.
    Mol Biol Rep. 2023 Aug 17. doi: 10.1007/s11033-023-08667.
    PubMed    
    Abstract available

  100. MERTENS LS, Psutka SP, Mir MC
    Bladder cancer oligometastases - definition and treatment.
    Nat Rev Urol. 2023 Aug 17. doi: 10.1038/s41585-023-00815.
    PubMed    


  101. FONT A, Domenech M, Ramirez JL, Marques M, et al
    Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features.
    Front Oncol. 2023;13:1155244.
    PubMed    
    Abstract available

  102. CHEN R, Hao X, Chen J, Zhang C, et al
    Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1.
    J Transl Med. 2023;21:549.
    PubMed    
    Abstract available

  103. XIA C, Zhao X, Li B, Qi B, et al
    Loneliness, spiritual well-being, and death perception, as well as their risk factors in urological cancer patients.
    Braz J Med Biol Res. 2023;56:e12915.
    PubMed    
    Abstract available

  104. XING Z, Ji M, Shan Y, Dong Z, et al
    Using the Multidimensional Health Locus of Control Scale Form C to Investigate Health Beliefs About Bladder Cancer Prevention and Treatment Among Male Patients: Cross-Sectional Study.
    JMIR Form Res. 2023;7:e43345.
    PubMed    
    Abstract available

  105. YANG C, Ou Y, Zhou Q, Liang Y, et al
    Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment.
    Cell Death Dis. 2023;14:525.
    PubMed    
    Abstract available

  106. VANIN MORENO N, Whitehead M, Siemens DR
    Real-life benchmarking bladder cancer care: A population-based study.
    Can Urol Assoc J. 2023;17:268-273.
    PubMed    
    Abstract available

  107. LIU W, Chen R, Liu X, Zhou B, et al
    Differentiation of bladder cancer stages using the vesical imaging -reporting and data system and apparent diffusion coefficient.
    Quant Imaging Med Surg. 2023;13:4897-4907.
    PubMed    
    Abstract available

  108. LI HZ, Zhu J, Weng GJ, Li JJ, et al
    Application of nanotechnology in bladder cancer diagnosis and therapeutic drug delivery.
    J Mater Chem B. 2023 Aug 15. doi: 10.1039/d3tb01323.
    PubMed    
    Abstract available

  109. ZHOU Q, Wu H, Miao F, Cao Y, et al
    Codelivery of ERCC2 small interfering RNA and cisplatin with macrophage-derived mimetic nanovesicles for enhanced bladder cancer treatment.
    Anticancer Drugs. 2023 Aug 15. doi: 10.1097/CAD.0000000000001528.
    PubMed    
    Abstract available

  110. SLUSARCZYK A, Zapala P, Zapala L, Borkowski T, et al
    Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis.
    Ann Surg Oncol. 2023 Aug 14. doi: 10.1245/s10434-023-14051.
    PubMed    
    Abstract available

  111. LIN F, Ke ZB, Xue YT, Chen JY, et al
    A novel CD8(+) T cell-related gene signature for predicting the prognosis and immunotherapy efficacy in bladder cancer.
    Inflamm Res. 2023 Aug 14. doi: 10.1007/s00011-023-01772.
    PubMed    
    Abstract available

  112. WONG MCS, Huang J, Wang HHX, Yau STY, et al
    Risk prediction of bladder cancer among diabetes patients: a derivation and validation study.
    Diabet Med. 2023 Aug 14:e15199. doi: 10.1111/dme.15199.
    PubMed    
    Abstract available

  113. CHANG S, Giannico GA, Haugen E, Jardaneh A, et al
    Multiparameter interferometric polarization-enhanced imaging differentiates carcinoma in situ from inflammation of the bladder: an ex vivo study.
    J Biomed Opt. 2023;28:102907.
    PubMed    
    Abstract available

  114. ROHITH G, Gaur AS, Nayak P, Mandal S, et al
    Socio-economic, education, and insurance-related factors associated with the treatment completion rates in patients with nonmetastatic urinary bladder cancer: A Retrospective cohort study.
    Indian J Urol. 2023;39:228-235.
    PubMed    
    Abstract available

  115. YAN D, He Q, Pei L, Yang M, et al
    The APC/C E3 ligase subunit ANAPC11 mediates FOXO3 protein degradation to promote cell proliferation and lymph node metastasis in urothelial bladder cancer.
    Cell Death Dis. 2023;14:516.
    PubMed    
    Abstract available

  116. HSU CW, Cheng NC, Liao MY, Cheng TY, et al
    Correction: Hsu et al. Development of Folic Acid-Conjugated and Methylene Blue-Adsorbed Au@TNA Nanoparticles for Enhanced Photodynamic Therapy of Bladder Cancer Cells. Nanomaterials 2020, 10, 1351.
    Nanomaterials (Basel). 2023;13:2233.
    PubMed    
    Abstract available

  117. FIORENTINO V, Pizzimenti C, Franchina M, Rossi ED, et al
    Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples.
    Int J Mol Sci. 2023;24:12489.
    PubMed    
    Abstract available

  118. PATWARDHAN MV, Mahendran R
    The Bladder Tumor Microenvironment Components That Modulate the Tumor and Impact Therapy.
    Int J Mol Sci. 2023;24:12311.
    PubMed    
    Abstract available

  119. MURALISANKAR M, Chen JR, Haribabu J, Ke SC, et al
    Effective and Selective Ru(II)-Arene Complexes Containing 4,4'-Substituted 2,2' Bipyridine Ligands Targeting Human Urinary Bladder Cancer Cells.
    Int J Mol Sci. 2023;24:11896.
    PubMed    
    Abstract available

  120. SERRANO M, Munoz-Unceta N, Alonso LA, Azueta A, et al
    Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience.
    Clin Transl Oncol. 2023 Aug 11. doi: 10.1007/s12094-023-03277.
    PubMed    
    Abstract available

  121. BASAK D, Mondal S, Srivastava SK, Sarkar D, et al
    Intratumoral PD1(+)CD38(+)Tim3(+) CD8(+) T Cells in Pre-BCG Tumor Tissues Are Associated with Poor Responsiveness to BCG Immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer.
    Cells. 2023;12:1939.
    PubMed    
    Abstract available

  122. RASTI A, Abazari O, Dayati P, Kardan Z, et al
    Identification of Potential Key Genes Linked to Gender Differences in Bladder Cancer Based on Gene Expression Omnibus (GEO) Database.
    Adv Biomed Res. 2023;12:157.
    PubMed    
    Abstract available

  123. LV J, Wu Q, Li K, Bai K, et al
    Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade.
    Int J Biol Sci. 2023;19:3744-3761.
    PubMed    
    Abstract available

  124. CHENG H, Liu Y, Chen G
    Identification of potential DNA methylation biomarkers related to diagnosis in patients with bladder cancer through integrated bioinformatic analysis.
    BMC Urol. 2023;23:135.
    PubMed    
    Abstract available

  125. STONE L
    Subtypes in small cell bladder cancer.
    Nat Rev Urol. 2023 Aug 10. doi: 10.1038/s41585-023-00813.
    PubMed    


  126. STONE L
    Proteomic characterization of bladder cancer.
    Nat Rev Urol. 2023 Aug 10. doi: 10.1038/s41585-023-00814.
    PubMed    


  127. ECKSTEIN M, Matek C, Wagner P, Erber R, et al
    Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.
    Eur Urol Oncol. 2023 Aug 8:S2588-9311(23)00153-0. doi: 10.1016/j.euo.2023.
    PubMed    
    Abstract available

  128. LIU Z, Zheng X, Chen J, Zheng L, et al
    NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer.
    Cell Rep. 2023;42:112963.
    PubMed    
    Abstract available

  129. FUNAKOSHI Y, Kanda S, Akihama S, Horikawa Y, et al
    [A Case of Inflammatory Myofibroblastic Tumor of The Bladder Treated with Partial Cystectomy].
    Hinyokika Kiyo. 2023;69:179-182.
    PubMed    
    Abstract available

  130. HASELAGER D, Dorigo-Zetsma W, Schroder M, Heidt J, et al
    An 80-Year-Old Man With Respiratory Insufficiency After Intravesical Mycobacterium bovis BCG Immunotherapy.
    Chest. 2023;164:e39-e43.
    PubMed    
    Abstract available

  131. SONG Y, Peng Y, Qin C
    Relationship between sex and immune checkpoint inhibitors in urothelial carcinoma and renal cell carcinoma.
    World J Urol. 2023;41:2301-2302.
    PubMed    


  132. BRUSASCO C, Di Domenico A, Ennas M, Benelli A, et al
    Application of a protocol for enhanced recovery after radical cystectomy: a before-and-after cohort study.
    World J Urol. 2023;41:2273-2280.
    PubMed    
    Abstract available

  133. CHANG YH, Hsu WL, Lee YK, Chiang CJ, et al
    Trends and sex-specific incidence of upper urinary tract cancer in Taiwan: A birth cohort study.
    Cancer Med. 2023;12:15350-15357.
    PubMed    
    Abstract available

  134. HE W, Chen C, Lin T, Xu Q, et al
    Epidemiology, treatments, and related biomarkers of locally advanced or metastatic urothelial carcinoma in Chinese population: A scoping review.
    Cancer Med. 2023;12:15384-15403.
    PubMed    
    Abstract available

  135. WU S, Li R, Jiang Y, Yu J, et al
    Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications.
    Biomed Pharmacother. 2023;165:115027.
    PubMed    
    Abstract available

  136. JI J, Yao Y, Sun L, Yang Q, et al
    Development and validation of a preoperative nomogram to predict lymph node metastasis in patients with bladder urothelial carcinoma.
    J Cancer Res Clin Oncol. 2023;149:10911-10923.
    PubMed    
    Abstract available

  137. SANTONI M, Myint ZW, Buttner T, Takeshita H, et al
    Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
    Cancer Immunol Immunother. 2023;72:2961-2970.
    PubMed    
    Abstract available

  138. LIN J, Ding M, Qin C, Song Y, et al
    A robust gene prognostic index composed of GZMB, IRF1, and TP63 can stratify the risk of two metastatic urothelial carcinoma cohorts based on immune checkpoint blockade therapy.
    J Cancer Res Clin Oncol. 2023;149:9877-9890.
    PubMed    
    Abstract available

  139. HUANG H, Li L, Cao Q, Tan H, et al
    Ectopic prostate tissue at the bladder.
    Am J Med Sci. 2023;366:e37.
    PubMed    


  140. REISWICH V, Schmidt CE, Lennartz M, Hoflmayer D, et al
    GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
    Pathobiology. 2023;90:219-232.
    PubMed    
    Abstract available

  141. ZIDAN ASA, Ibrahim ABM, Aly AAM, Mosbah HK, et al
    Synthesis, Solid State Structure, and Cytotoxic Activity of a Complex Dimer of Yttrium with Anthranilic Acid against Cancer Cells.
    Biol Trace Elem Res. 2023;201:4688-4696.
    PubMed    
    Abstract available

  142. LOBO J, Lobo C, Leca L, Rodrigues A, et al
    Evaluation of the Implementation and Diagnostic Accuracy of the Paris Classification for Reporting Urinary Cytology in Voided Urine Specimens: A Cyto-Histological Correlation Study in a Cancer Center.
    Pathobiology. 2023;90:233-240.
    PubMed    
    Abstract available

  143. ZHANG T, Chen L, Xu X, Shen C, et al
    Knockdown of Long Noncoding RNA Urothelial Carcinoma-Associated 1 Represses Gallbladder Cancer Advancement by Regulating SPOCK1 Expression Through Sponging miR-613.
    Cancer Biother Radiopharm. 2023;38:354-363.
    PubMed    
    Abstract available

  144. RYSANKOVA K, Gumulec J, Grepl M, Krhut J, et al
    Acquired haemophilia as a complicating factor in treatment of non-muscle invasive bladder cancer: A case report.
    World J Clin Cases. 2023;11:5338-5343.
    PubMed    
    Abstract available

  145. LI H, Jiang H, Huang Z, Chen Z, et al
    Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  146. LI K, Li S, Tang S, Zhang M, et al
    [Retracted] KIF22 promotes bladder cancer progression by activating the expression of CDCA3.
    Int J Mol Med. 2023;52:92.
    PubMed    
    Abstract available

  147. SHEN J, Du M, Liang S, Wang L, et al
    Construction of a cuproptosis-associated lncRNA prognostic signature for bladder cancer and experimental validation of cuproptosis-related lncRNA UBE2Q1-AS1.
    Front Med (Lausanne). 2023;10:1222543.
    PubMed    
    Abstract available

  148. ALYUSUF Z, Hassan A, Maki R, Hasan W, et al
    Intravesical urachal cyst masquerading as a bladder malignancy: a case report.
    J Med Case Rep. 2023;17:364.
    PubMed    
    Abstract available

  149. ZHUANG J, Mo J, Huang Z, Yan Y, et al
    Mechanisms of Xiaozheng decoction for anti-bladder cancer effects via affecting the GSK3beta/beta-catenin signaling pathways: a network pharmacology-directed experimental investigation.
    Chin Med. 2023;18:104.
    PubMed    
    Abstract available

  150. ZHANG D, Yin G, Zheng S, Chen Q, et al
    Construction of a prediction model for prognosis of bladder cancer based on the expression of ion channel-related genes.
    Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023.
    PubMed    
    Abstract available

  151. KUMADA N, Nakane K, Yamada T, Tomioka-Inagawa R, et al
    Utility and safety of robot-assisted radical cystectomy in older patients with bladder cancer.
    Minim Invasive Ther Allied Technol. 2023.
    PubMed    
    Abstract available

  152. JIANG PC, Xu LZ, Ning JZ, Cheng F, et al
    GREM1 is a potential biomarker for the progression and prognosis of bladder cancer.
    World J Surg Oncol. 2023;21:255.
    PubMed    
    Abstract available

  153. TOREN P, Wilkins A, Patel K, Burley A, et al
    The sex gap in bladder cancer survival - a missing link in bladder cancer care?
    Nat Rev Urol. 2023 Aug 21. doi: 10.1038/s41585-023-00806.
    PubMed    
    Abstract available

  154. BASILE G, Pradere B, Bellmunt J, Roupret M, et al
    A Plea for the Use of Video-recorded Cystoscopy for Blinded Independent Central Review of Tumor Response in Open-label Non-muscle invasive Bladder Cancer Trials.
    Eur Urol Oncol. 2023 Aug 19:S2588-9311(23)00147.
    PubMed    
    Abstract available

  155. FUKUHARA H, Hagiwara Y, Oba K, Inoue K, et al
    Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (3rd report): cost impact of transurethral resection of bladder tumor in Japan.
    Photodiagnosis Photodyn Ther. 2023 Aug 19:103758.
    PubMed    
    Abstract available

  156. HAN D, Guan L, Zhang Y, Yang H, et al
    FGF13A interacts with NPM1 and UBF and inhibits the invasion of bladder cancer cells.
    Biochem Biophys Res Commun. 2023;678:1-10.
    PubMed    
    Abstract available

  157. WEI X, Chai Y, Li Z, Che X, et al
    Up-regulated serum lactate dehydrogenase could become a poor prognostic marker in patients with bladder cancer by an evidence-based analysis of 2,182 patients.
    Front Oncol. 2023;13:1233620.
    PubMed    
    Abstract available

  158. FANG D, He Y, Yi Y, Mei J, et al
    Hub gene associated with prognosis in bladder cancer is a novel therapeutic target.
    PeerJ. 2023;11:e15670.
    PubMed    
    Abstract available

  159. TAN Z, Chen X, Zuo J, Fu S, et al
    Integrating Bulk and Single-Cell RNA Sequencing Reveals Heterogeneity, Tumor Microenvironment, and Immunotherapeutic Efficacy Based on Sialylation-Related Genes in Bladder Cancer.
    J Inflamm Res. 2023;16:3399-3417.
    PubMed    
    Abstract available

  160. SU W, Sui W, Cheng X, Zong Y, et al
    Morphology, immunohistochemistry characteristics, and clinical presentation of microcystic urothelial carcinoma: a series of 10 cases.
    Diagn Pathol. 2023;18:94.
    PubMed    
    Abstract available

  161. KIM DK, Kim JH, Park JY, Gwon YN, et al
    Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer With Variant Histology: A Systematic Review and Meta-Analysis of Survival Outcomes and Pathological Features.
    Clin Genitourin Cancer. 2023 Jul 8:S1558-7673(23)00172.
    PubMed    
    Abstract available

  162. ELSALEM L, Al Shatnawi A, A Alfaqih M, Alshoh A, et al
    Discovery of a novel genetic variant in the N-acetyltransferase2 (NAT2) gene that is associated with bladder cancer risk.
    Acta Biochim Pol. 2023 Aug 18. doi: 10.18388/abp.2020_6590.
    PubMed    
    Abstract available

  163. CHEN X, Liao C, Zou X, Zhang B, et al
    A gene signature of cancer-associated fibroblasts predicts prognosis and treatment response in bladder cancer.
    Clin Transl Oncol. 2023 Aug 18. doi: 10.1007/s12094-023-03270.
    PubMed    
    Abstract available

  164. KIM S, Park J, Ho JN, Kim D, et al
    3D vascularized microphysiological system for investigation of tumor-endothelial crosstalk in anti-cancer drug resistance.
    Biofabrication. 2023;15.
    PubMed    
    Abstract available

  165. KONOREV D, Bellamri M, Wu CF, Wu MT, et al
    High-Field Asymmetric Waveform Ion Mobility Spectrometry Analysis of Carcinogenic Aromatic Amines in Tobacco Smoke with an Orbitrap Tribrid Mass Spectrometer.
    Chem Res Toxicol. 2023;36:1419-1426.
    PubMed    
    Abstract available

  166. LIU Z, Wei S, Tang J
    Clinicopathologic Features of Noninvasive Inverted Urothelial Papillary Tumor.
    Am J Clin Oncol. 2023;46:409-413.
    PubMed    
    Abstract available

  167. LU J, Cai S, Wang F, Wu PY, et al
    Development of a prediction model for gross residual in high-grade serous ovarian cancer by combining preoperative assessments of abdominal and pelvic metastases and multiparametric MRI.
    Acad Radiol. 2023;30:1823-1831.
    PubMed    
    Abstract available

  168. ARAI T, Sazuka T, Oka R, Tsukamoto R, et al
    Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted Bladder Biopsy: Japanese Real-world Study.
    Anticancer Res. 2023;43:3615-3621.
    PubMed    
    Abstract available

  169. CONTIERI R, Grajales V, Tan WS, Martini A, et al
    Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
    BJU Int. 2023 Jul 13. doi: 10.1111/bju.16127.
    PubMed    
    Abstract available

  170. LAUKHTINA E, von Deimling M, Pradere B, Yanagisawa T, et al
    Urinary function in female patients after traditional, organ-and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analyses.
    BJU Int. 2023 Aug 10. doi: 10.1111/bju.16152.
    PubMed    
    Abstract available

  171. ZAHRAN MH, Harraz AM, Baset MA, El-Baz R, et al
    Voiding and renal function 10 years after radical cystectomy and orthotopic neobladder in women.
    BJU Int. 2023;132:291-297.
    PubMed    
    Abstract available

  172. LU J, Lai J, Xiao K, Peng S, et al
    A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study.
    Br J Cancer. 2023 Aug 4. doi: 10.1038/s41416-023-02383.
    PubMed    
    Abstract available

  173. LIU B, Fu X, Du Y, Feng Z, et al
    Pan-cancer analysis of G6PD carcinogenesis in human tumors.
    Carcinogenesis. 2023;44:525-534.
    PubMed    
    Abstract available

  174. ZHANG R, Zang J, Jin D, Xie F, et al
    Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer.
    Clin Cancer Res. 2023 Aug 3:CCR-23-0513. doi: 10.1158/1078-0432.CCR-23-0513.
    PubMed    
    Abstract available

  175. SUSSMAN J, Konety B, Ahmadi H
    Re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer. NEJM Evid 2022;1:EVIDoa2200092.
    Eur Urol. 2023 Aug 12:S0302-2838(23)03017-8. doi: 10.1016/j.eururo.2023.
    PubMed    


  176. BLACK PC, Tangen CM, Singh P, McConkey DJ, et al
    Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
    Eur Urol. 2023 Aug 16:S0302-2838(23)03019-1. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  177. MIYAKE M, Nishimura N, Fujii T, Fujimoto K, et al
    Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Int J Urol. 2023 Jul 31. doi: 10.1111/iju.15263.
    PubMed    
    Abstract available

  178. GOTO Y
    Editorial Comment to Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:647-648.
    PubMed    


  179. YOSHIDA T, Ohe C, Nakamoto T, Kinoshita H, et al
    Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:634-647.
    PubMed    
    Abstract available

  180. KONDO T
    Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:657.
    PubMed    


  181. SAZUKA T
    Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:658.
    PubMed    


  182. OKUYAMA Y, Hatakeyama S, Tabata R, Fujimori D, et al
    Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:649-657.
    PubMed    
    Abstract available

  183. HAGIMOTO H, Kambe T, Mine Y, Kokubun H, et al
    Necessity of prophylactic drainage tube in retroperitoneal laparoscopic nephroureterectomy with open distal ureterectomy: A matched-pair analysis.
    Int J Urol. 2023;30:579-584.
    PubMed    
    Abstract available

  184. ISHII N, Hatakeyama S, Miura H, Tanaka R, et al
    Trends in the age of hospitalized patients with urological cancers: A 17-year experience.
    Int J Urol. 2023;30:572-578.
    PubMed    
    Abstract available

  185. GOTO Y
    Editorial Comment to Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15286.
    PubMed    


  186. NISHIMURA N, Miyake M, Nakahama T, Miyamoto T, et al
    Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15283.
    PubMed    
    Abstract available

  187. LIANG HQ, Liao NK, Yang SB, Wei QJ, et al
    Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
    Int J Urol. 2023 Aug 21. doi: 10.1111/iju.15276.
    PubMed    
    Abstract available

  188. OSMAN Y, Elawdy M, Taha DE, Zahran MH, et al
    Bladder perforation as a complication of transurethral resection of bladder tumors: the predictors, management, and its impact in a series of 1570 at a tertiary urology institute.
    Int Urol Nephrol. 2023;55:2161-2167.
    PubMed    
    Abstract available

  189. WANG IK, Yu TM, Yen TH, Lin CL, et al
    Comparison of the risks of renal cell carcinoma or urothelial cancer between hemodialysis and peritoneal dialysis patients.
    Int Urol Nephrol. 2023;55:2267-2274.
    PubMed    
    Abstract available

  190. VON DER MAASE H, Hansen SW, Roberts JT, Dogliotti L, et al
    Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
    J Clin Oncol. 2023;41:3881-3890.
    PubMed    
    Abstract available

  191. SMALL EJ
    Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
    J Clin Oncol. 2023;41:3879-3880.
    PubMed    


  192. TAN WS, Contieri R, Buffi NM, Lughezzani G, et al
    International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts Outcomes of Patients on Active Surveillance.
    J Urol. 2023 Aug 3:101097JU0000000000003639. doi: 10.1097/JU.0000000000003639.
    PubMed    
    Abstract available

  193. PRASAD SM, Huang WC, Shore ND, Hu B, et al
    Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
    J Urol. 2023 Aug 7:101097JU0000000000003645. doi: 10.1097/JU.0000000000003645.
    PubMed    
    Abstract available

  194. CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Reply.
    J Urol. 2023;210:408.
    PubMed    


  195. WONG N, So WZ, Tiong HY
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Letter.
    J Urol. 2023;210:407-408.
    PubMed    


  196. XIE J, Zhang H, Wang K, Ni J, et al
    M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription.
    Oncogene. 2023 Aug 23. doi: 10.1038/s41388-023-02814.
    PubMed    
    Abstract available

  197. HAO Y, He W, Wang H, Rui W, et al
    Forkhead box F1 functions as a novel prognostic biomarker and induces caspase‑dependent apoptosis in bladder cancer.
    Oncol Rep. 2023;50:173.
    PubMed    
    Abstract available

  198. WU YL, Li ZQ, Wu AM
    The Misdiagnosis of Intravesical Ectopic Prostatic Tissue as a Tumor.
    Urol Int. 2023;107:738-741.
    PubMed    
    Abstract available

  199. JEVNIKAR B, Slopnick E, Almassi N
    Clinical Challenge in Urology: Late Genitourinary Toxicity Following Intravesical Bacillus Calmette-Guerin.
    Urology. 2023;177:e8-e9.
    PubMed    


  200. GELDMAKER LE, Baird BA, Hasse CH, Haehn DA, et al
    Analysis of Transurethral Resection of Bladder Tumor Efficiency Utilizing Nonprocedural Operating Room Times.
    Urology. 2023;177:6-11.
    PubMed    
    Abstract available

  201. KANABOLO DL, Park S
    Prophylactic Mesh Placement With Ileal Conduit: A Cost-effectiveness Analysis.
    Urology. 2023;177:197-203.
    PubMed    
    Abstract available

  202. FENG S, Yang Y, Yu Z, Xiong Q, et al
    Survival and Analysis of Prognostic Factors for Bladder Malignancies in Children and Adolescents: A Population-based Study.
    Urology. 2023;177:156-161.
    PubMed    
    Abstract available

  203. SOYSTER ME, Arnold PJ, Burns RT, Zappia JL, et al
    Ileal Ureter Utilization in Patients With Previous Urinary Diversions.
    Urology. 2023;177:184-188.
    PubMed    
    Abstract available

  204. RANTI D, Dey L, Bieber C, Grauer R, et al
    Surveillance for Non-Muscle Invasive Bladder Cancer: Identifying the point of Diminishing Returns.
    Urology. 2023 Aug 19:S0090-4295(23)00697-0. doi: 10.1016/j.urology.2023.
    PubMed    
    Abstract available

  205. JIANG Y, Zhu C, Huang H, Huang G, et al
    TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
    BMC Cancer. 2023;23:716.
    PubMed    
    Abstract available

  206. CAI Y, Cheng Y, Wang Z, Li L, et al
    A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    BMC Cancer. 2023;23:725.
    PubMed    
    Abstract available

  207. WONG JL, Smith P, Angulo-Lozano J, Ranti D, et al
    IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2306782120.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;